Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Dexpramipexole (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWER
- Sponsors Biogen; Knopp Biosciences
- 09 Jul 2019 According to an Knopp Biosciences media release, the analysis of the eosinophil-lowering effects of dexpramipexole seen in this study will be presented at the 11th Biennial Symposium of the International Eosinophil Society.
- 30 Nov 2017 According to a Cytokinetics media release, retrospective analysis data from EMPOWER, BENEFIT-ALS and Open-Access ALS Clinical Trials (PRO-ACT) database were published in the Journal of the American Medical Association (JAMA) Neurology.
- 30 Nov 2017 Retrospective data was published in a Cytokinetics media release.